$Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients$
Código QR

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients

Objective: High-dose ascorbic acid leads to the formation of highly reactive oxygen species due to the pro-oxidant effect, resulting in cell death; therefore, used as an additive treatment in several malignancies. We present the results obtained by administration of pharmacological dose of ascorbic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ali Zahit Bolaman, Atakan Turgutkaya, Hilal Eroğlu Küçükdiler, Cem Selim, İrfan Yavaşoğlu
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Arsenic Ascorbate Intravenous Oxidative Reactive oxygen species Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6b3b5fbaa5164aafa888dc758d920cf1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6b3b5fbaa5164aafa888dc758d920cf1
record_format	dspace
spelling	oai:doaj.org-article:6b3b5fbaa5164aafa888dc758d920cf12021-11-26T04:28:45ZPharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients2213-048910.1016/j.lrr.2021.100281https://doaj.org/article/6b3b5fbaa5164aafa888dc758d920cf12021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2213048921000480https://doaj.org/toc/2213-0489Objective: High-dose ascorbic acid leads to the formation of highly reactive oxygen species due to the pro-oxidant effect, resulting in cell death; therefore, used as an additive treatment in several malignancies. We present the results obtained by administration of pharmacological dose of ascorbic acid to conventional chemotherapy in relapsed refractory multiple myeloma patients. Materials-methods: Intravenous ascorbic acid at a pharmacologic dose of 15 gram/week was added to the chemotherapy regimen of relapsed refractory multiple myeloma patients, who received carfilzomib-lenalidomide-dexamethasone treatment and did not respond after the second cycle. Results: The total of 4 patients who had previously received 6–9 lines of myeloma treatment were included. After 4 cycles of chemotherapy + ascorbic acid combination, 1 patient had a complete response whereas other patients had a very good partial response. Conclusion: The addition of pharmacological dose ascorbic acid to conventional chemotherapy can be an effective approach in relapsed refractory patients. Clinical studies with a large number of patients will be useful to evaluate the pharmacological dose of ascorbate in plasma cell disorders.Ali Zahit BolamanAtakan TurgutkayaHilal Eroğlu KüçükdilerCem Selimİrfan YavaşoğluElsevierarticleArsenicAscorbateIntravenousOxidativeReactive oxygen speciesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLeukemia Research Reports, Vol 16, Iss , Pp 100281- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arsenic Ascorbate Intravenous Oxidative Reactive oxygen species Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Arsenic Ascorbate Intravenous Oxidative Reactive oxygen species Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ali Zahit Bolaman Atakan Turgutkaya Hilal Eroğlu Küçükdiler Cem Selim İrfan Yavaşoğlu Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
description	Objective: High-dose ascorbic acid leads to the formation of highly reactive oxygen species due to the pro-oxidant effect, resulting in cell death; therefore, used as an additive treatment in several malignancies. We present the results obtained by administration of pharmacological dose of ascorbic acid to conventional chemotherapy in relapsed refractory multiple myeloma patients. Materials-methods: Intravenous ascorbic acid at a pharmacologic dose of 15 gram/week was added to the chemotherapy regimen of relapsed refractory multiple myeloma patients, who received carfilzomib-lenalidomide-dexamethasone treatment and did not respond after the second cycle. Results: The total of 4 patients who had previously received 6–9 lines of myeloma treatment were included. After 4 cycles of chemotherapy + ascorbic acid combination, 1 patient had a complete response whereas other patients had a very good partial response. Conclusion: The addition of pharmacological dose ascorbic acid to conventional chemotherapy can be an effective approach in relapsed refractory patients. Clinical studies with a large number of patients will be useful to evaluate the pharmacological dose of ascorbate in plasma cell disorders.
format	article
author	Ali Zahit Bolaman Atakan Turgutkaya Hilal Eroğlu Küçükdiler Cem Selim İrfan Yavaşoğlu
author_facet	Ali Zahit Bolaman Atakan Turgutkaya Hilal Eroğlu Küçükdiler Cem Selim İrfan Yavaşoğlu
author_sort	Ali Zahit Bolaman
title	Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
title_short	Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
title_full	Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
title_fullStr	Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
title_full_unstemmed	Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
title_sort	pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/6b3b5fbaa5164aafa888dc758d920cf1
work_keys_str_mv	AT alizahitbolaman pharmacologicaldoseascorbicacidadministrationinrelapsedrefractorymultiplemyelomapatients AT atakanturgutkaya pharmacologicaldoseascorbicacidadministrationinrelapsedrefractorymultiplemyelomapatients AT hilaleroglukucukdiler pharmacologicaldoseascorbicacidadministrationinrelapsedrefractorymultiplemyelomapatients AT cemselim pharmacologicaldoseascorbicacidadministrationinrelapsedrefractorymultiplemyelomapatients AT irfanyavasoglu pharmacologicaldoseascorbicacidadministrationinrelapsedrefractorymultiplemyelomapatients
_version_	1718409846144892928

Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients

Ejemplares similares